(Q33797891)

English

The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Hepatitis C virus

1 reference

based on heuristic

Katarzyna Gawlik

4

object named as

Katarzyna Gawlik

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

author name string

Udayan Chatterji

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Jose A Garcia-Rivera

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

James Baugh

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Kelly A Wong

5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Weidong Zhong

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Clifford A Brass

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Nikolai V Naoumov

8

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Philippe A Gallay

9

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

0 references

publication date

31 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

58

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

3327-3334

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Completion of the entire hepatitis C virus life cycle in genetically humanized mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068438

28 July 2018

The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068438

28 July 2018

Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068438

28 July 2018

Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068438

28 July 2018

Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068438

28 July 2018

A conserved tandem cyclophilin-binding site in hepatitis C virus nonstructural protein 5A regulates Alisporivir susceptibility

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068438

28 July 2018

DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068438

28 July 2018

Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068438

28 July 2018

Epidemiology of hepatitis C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068438

28 July 2018

Characterization of the Early Steps of Hepatitis C Virus Infection by Using Luciferase Reporter Viruses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068438

28 July 2018

American Gastroenterological Association technical review on the management of hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068438

28 July 2018

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068438

28 July 2018

Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068438

28 July 2018

A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068438

28 July 2018

A three-dimensional model to analyze drug-drug interactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068438

28 July 2018

Characterizations of HCV NS5A replication complex inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068438

30 October 2018

Curing a viral infection by targeting the host: the example of cyclophilin inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068438

30 October 2018

Profile of alisporivir and its potential in the treatment of hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068438

30 October 2018

Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068438

30 October 2018

Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068438

30 October 2018

All three domains of the hepatitis C virus nonstructural NS5A protein contribute to RNA binding

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068438

30 October 2018

Emerging drugs for hepatitis C

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4068438

30 October 2018

Identifiers

10.1128/AAC.00016-14

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33797891&oldid=1533801974"